RE: lack of liquidity here.. is causing..21 Sep 2022 12:59
I was invested in another similar "contrasting" company elsewhere at the time of the last submission but was watching this one closely. Rightly or wrongly, I just felt that POLX was not paying the level of attention to detail that an FDA submission merits. They just seemed to be taking it as a 'given'. Things like a lack of communication with shareholders and no recent online presentations from the CEO made me wary. Proactive info and responses seemed to be lacking too. They still haven't told us in any real detail about the reason behind the CRL (Yes, I know about the change of contractor but much of that seems to have been hearsay rather than from the horse's mouth). I am invested now but if we fail this time, especially on pretty basic technicals again, then they really don't deserve to be in business. I am hopeful they have grasped that.